Immunmoduláló antitestek alkalmazása - Az onkológia új fejezete

Translated title of the contribution: Application of immunomodulatory therapeutic antibodies - A new perspective in oncology

Szamosi Szilvia, Váróczy László, Z. Szekanecz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the past decade major advances in tumor immunology, a better understanding of antigen recognition by T-cells likewise discovering the regulatory inhibitory signals resulted in the development of new immunotherapies with promising durable responses in various solid tumor types and in hematologic malignancies. This review focuses on immunomodulatory antibodies, namely immune checkpoint inhibitor therapy. The prototype of this new class of immune stimulating agents was cytotoxic T-lymphocyte antigen-4 (CTLA-4) antagonists. After demonstrating enhanced survival, ipilimumab was approved first in the United States in 2011, further on in the European Union for second-line (2011) and for first-line therapy (2013) of metastatic melanoma. Additional T-cell intrinsic pathways were identified and targeted for clinical development. Antibodies blocking the PD-1 pathway also showed promising clinical activity and objective tumor response in several types of tumors, including metastatic melanoma, non-smallcell lung cancer. On the other hand antitumor activity is frequently accompanied by significant reversible immunerelated adverse events. To explore potential new immune checkpoint targets bring forth several challanges. Future clinical development will involve identifying potential biomarkers anticipating responsiveness to pathway blockade and additional tumor types likely to respond to the therapy. Furthermore, combination strategies, immune checkpoint inhibitors combined with cancer vaccines, targeted inhibitors and traditional chemotherapies are being evaluated in pre-clinical studies.

Original languageHungarian
Pages (from-to)9-16
Number of pages8
JournalOrvosi Hetilap
Volume157
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Antibodies
Neoplasms
Melanoma
CTLA-4 Antigen
T-Lymphocytes
Therapeutics
Cancer Vaccines
Blocking Antibodies
Hematologic Neoplasms
European Union
Allergy and Immunology
Immunotherapy
Lung Neoplasms
Biomarkers
Antigens
Drug Therapy
Clinical Studies
ipilimumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immunmoduláló antitestek alkalmazása - Az onkológia új fejezete. / Szilvia, Szamosi; László, Váróczy; Szekanecz, Z.

In: Orvosi Hetilap, Vol. 157, 01.06.2016, p. 9-16.

Research output: Contribution to journalArticle

Szilvia, Szamosi ; László, Váróczy ; Szekanecz, Z. / Immunmoduláló antitestek alkalmazása - Az onkológia új fejezete. In: Orvosi Hetilap. 2016 ; Vol. 157. pp. 9-16.
@article{10260542951e475d9a24add040af3765,
title = "Immunmodul{\'a}l{\'o} antitestek alkalmaz{\'a}sa - Az onkol{\'o}gia {\'u}j fejezete",
abstract = "In the past decade major advances in tumor immunology, a better understanding of antigen recognition by T-cells likewise discovering the regulatory inhibitory signals resulted in the development of new immunotherapies with promising durable responses in various solid tumor types and in hematologic malignancies. This review focuses on immunomodulatory antibodies, namely immune checkpoint inhibitor therapy. The prototype of this new class of immune stimulating agents was cytotoxic T-lymphocyte antigen-4 (CTLA-4) antagonists. After demonstrating enhanced survival, ipilimumab was approved first in the United States in 2011, further on in the European Union for second-line (2011) and for first-line therapy (2013) of metastatic melanoma. Additional T-cell intrinsic pathways were identified and targeted for clinical development. Antibodies blocking the PD-1 pathway also showed promising clinical activity and objective tumor response in several types of tumors, including metastatic melanoma, non-smallcell lung cancer. On the other hand antitumor activity is frequently accompanied by significant reversible immunerelated adverse events. To explore potential new immune checkpoint targets bring forth several challanges. Future clinical development will involve identifying potential biomarkers anticipating responsiveness to pathway blockade and additional tumor types likely to respond to the therapy. Furthermore, combination strategies, immune checkpoint inhibitors combined with cancer vaccines, targeted inhibitors and traditional chemotherapies are being evaluated in pre-clinical studies.",
keywords = "CTLA-4, Immuno-oncology, Immunomodulatory antibodies, PD-1",
author = "Szamosi Szilvia and V{\'a}r{\'o}czy L{\'a}szl{\'o} and Z. Szekanecz",
year = "2016",
month = "6",
day = "1",
doi = "10.1556/OH.2016.30507",
language = "Hungarian",
volume = "157",
pages = "9--16",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",

}

TY - JOUR

T1 - Immunmoduláló antitestek alkalmazása - Az onkológia új fejezete

AU - Szilvia, Szamosi

AU - László, Váróczy

AU - Szekanecz, Z.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - In the past decade major advances in tumor immunology, a better understanding of antigen recognition by T-cells likewise discovering the regulatory inhibitory signals resulted in the development of new immunotherapies with promising durable responses in various solid tumor types and in hematologic malignancies. This review focuses on immunomodulatory antibodies, namely immune checkpoint inhibitor therapy. The prototype of this new class of immune stimulating agents was cytotoxic T-lymphocyte antigen-4 (CTLA-4) antagonists. After demonstrating enhanced survival, ipilimumab was approved first in the United States in 2011, further on in the European Union for second-line (2011) and for first-line therapy (2013) of metastatic melanoma. Additional T-cell intrinsic pathways were identified and targeted for clinical development. Antibodies blocking the PD-1 pathway also showed promising clinical activity and objective tumor response in several types of tumors, including metastatic melanoma, non-smallcell lung cancer. On the other hand antitumor activity is frequently accompanied by significant reversible immunerelated adverse events. To explore potential new immune checkpoint targets bring forth several challanges. Future clinical development will involve identifying potential biomarkers anticipating responsiveness to pathway blockade and additional tumor types likely to respond to the therapy. Furthermore, combination strategies, immune checkpoint inhibitors combined with cancer vaccines, targeted inhibitors and traditional chemotherapies are being evaluated in pre-clinical studies.

AB - In the past decade major advances in tumor immunology, a better understanding of antigen recognition by T-cells likewise discovering the regulatory inhibitory signals resulted in the development of new immunotherapies with promising durable responses in various solid tumor types and in hematologic malignancies. This review focuses on immunomodulatory antibodies, namely immune checkpoint inhibitor therapy. The prototype of this new class of immune stimulating agents was cytotoxic T-lymphocyte antigen-4 (CTLA-4) antagonists. After demonstrating enhanced survival, ipilimumab was approved first in the United States in 2011, further on in the European Union for second-line (2011) and for first-line therapy (2013) of metastatic melanoma. Additional T-cell intrinsic pathways were identified and targeted for clinical development. Antibodies blocking the PD-1 pathway also showed promising clinical activity and objective tumor response in several types of tumors, including metastatic melanoma, non-smallcell lung cancer. On the other hand antitumor activity is frequently accompanied by significant reversible immunerelated adverse events. To explore potential new immune checkpoint targets bring forth several challanges. Future clinical development will involve identifying potential biomarkers anticipating responsiveness to pathway blockade and additional tumor types likely to respond to the therapy. Furthermore, combination strategies, immune checkpoint inhibitors combined with cancer vaccines, targeted inhibitors and traditional chemotherapies are being evaluated in pre-clinical studies.

KW - CTLA-4

KW - Immuno-oncology

KW - Immunomodulatory antibodies

KW - PD-1

UR - http://www.scopus.com/inward/record.url?scp=84975069850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975069850&partnerID=8YFLogxK

U2 - 10.1556/OH.2016.30507

DO - 10.1556/OH.2016.30507

M3 - Article

C2 - 27296505

AN - SCOPUS:84975069850

VL - 157

SP - 9

EP - 16

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

ER -